The same mRNA technology used in COVID-19 vaccines may offer a powerful new way to prevent long-term muscle damage caused by ...

Inside cells, RNAs and proteins form tiny, liquid-like droplets called biomolecular condensates. These droplets are essential for organizing cellular life, yet why some RNAs cluster more readily than ...

A new mRNA vaccine against the flu has proven itself more effective than existing vaccines in a new clinical trial. The ...

A flu vaccine that harnesses the messenger RNA technology that ended the COVID-19 pandemic appears increasingly likely, ...

According to researchers, the adapted treatment could help to prevent muscle damage and permanent physical impacts.

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...

French scientists in a lab in Orleans are turning their attention to the potential of mRNA – molecules used to quickly ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

The study was published in Nature Biotechnology last month and marks a shift in scientists’ understanding of how to efficiently cure specific diseases.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion ...